Shots:

• Medtronic to acquire all outstanding shares of Intersect ENT for $28.25/ share in cash- making a total deal value of ~$1.1B. The transaction is expected to be completed by H1’22
• The acquisition will expand Medtronic’s product portfolio which is used in the ENT procedure. Additionally- the acquisition will add a bioabsorbable drug release platform to the CRS portfolio
• Intersect ENT's PROPEL and SINUVA sinus implants will combine with Medtronic’s navigation- powered instruments- and existing tissue health products to provide solutions for patients suffering from CRS

  | Ref: PR Newswire | Image: Rasayanika